Literature DB >> 25206254

Safety Aspects of Antiretroviral Therapy for Management of HIV Infection.

R Rajesh1, Sudha Vidyasagar2, Naren Patel1.   

Abstract

There are four classes of antiretroviral agents used in the treatment of HIV/AIDS. Adverse effects to Highly Active Antiretroviral Therapy (HAART) are common and often difficult to avoid. In many cases, research is not able to identify the exact cause of an adverse event. The severity of adverse reactions varies greatly and difficult to manage; typically prevention is more desirable than treatment. However, this is not always true. This paper will review safety aspect of class-wide Highly Active Antiretroviral Therapy, mechanism of action. A class-wide adverse effect for Reverse transcriptase inhibitors includes lactic acidosis, peripheral neuropathy and lipoatrophy. Class wide adverse effects to non-nucleoside reverse transcriptase inhibitors include rash and hepatotoxicity, while efavirenz has its own unique CNS reactions. Protease inhibitor side effects include hyperglycemia, lipoaccumulation, dyslipidemia, and gastrointestinal (GI) intolerance. Coreceptor CCR5 antagonists, which provide a novel mechanism of action, are a recent addition to the armamentarium of antiretroviral agents. Antiretroviral are an important break-through in the treatment of HIV/AIDS. However, adverse reactions from these drugs can range from mild to life-threatening, and determining which agent is the cause is frequently difficult to discern. Fortunately, side effects can be monitored, treated and in many cases, prevented.

Entities:  

Keywords:  Adverse Drug Reactions; Antiretroviral Therapy; Management; Prevention; Safety

Year:  2010        PMID: 25206254      PMCID: PMC4158898     

Source DB:  PubMed          Journal:  J Basic Clin Pharm        ISSN: 0976-0113


  2 in total

1.  Association between Medication Adherence Outcomes and Adverse Drug Reactions to Highly Active Antiretroviral Therapy in Indian Human Immunodeficiency Virus-Positive Patients.

Authors:  R Rajesh; V Sudha; Dm Varma; S Sonika
Journal:  J Young Pharm       Date:  2012-10

2.  Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.

Authors:  Elżbieta Jabłonowska; Piotr Pulik; Anna Kalinowska; Jacek Gąsiorowski; Miłosz Parczewski; Monika Bociąga-Jasik; Elżbieta Mularska; Łukasz Pulik; Ewa Siwak; Kamila Wójcik
Journal:  Arch Med Sci       Date:  2016-09-22       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.